to 29% in AML when treated with DLT. [3][4][5] In our institution we treated a patient with AML in early relapse after allogeneic stem cell transplantation with a combination A 55-year-old woman with chemotherapy-resistant acute myeloblastic leukemia (AML M2) relapsed 3 consisting of withdrawal of immunosuppressive treatment, low-dose cytarabine and peripheral blood stem cells conmonths after allogeneic PBSC transplant. The patient was treated with two cycles of low-dose cytarabine taining donor lymphocytes. chemotherapy followed by G-CSF mobilized donor PBSC after cessation of all immunosuppressive treatment. Hematological and cytogenetic complete Case report remission was observed after the first cycle. The patient had been previously treated for AGVHD after allo-A 55-year-old female was admitted with AML (FAB M2, trisomy 8) in early relapse 3 months after induction chemogeneic PBSC transplantation and experienced a second AGVHD after the second cycles of cytoreductive treattherapy. She was treated with amsacrine and high-dose cytarabine which induced a second hematological CR with ment and donor PBSC infusion. Hematological recovery after donor PBSC infusion was faster than recovery persistence of the malignant clone 47XX +8. A matched related allogeneic PBSC transplant previously declined by after previous chemotherapy or high-dose chemotherapy. During treatment no febrile neutropenia was the patient was undertaken. Donor PBSC were mobilized by G-CSF 10 g/kg/day s.c. and collected by COBE Specobserved. This case shows that donor PBSC infusion cannot only provide prolonged complete hematological tra (COBE Laboratory, Lakewood, CO, USA). The donor was an HLA-compatible, ABO incompatible CMV-positive and cytogenetic remission but also seems to support accelerated hematopoietic recovery for some patients sister. Conditioning included etoposide, cyclophosphamide and total body irradiation (TBI). GVHD prophylaxis was relapsing after allogeneic BMT. Keywords: low-dose cytarabine; donor lymphocyte provided with cyclosporine A (CsA) and methotrexate (MTX). The patient developed acute grade II GVHD, infusion; marrow transplant; acute myeloid leukemia which responded poorly to prednisone (PDN) and finally resolved with anti-thymocyte globuline (ATG) and azathioprine. Patients presenting with early relapse after allogeneic bone Three months after transplant the patient relapsed. Chimmarrow transplantation (BMT) for acute myelogenous leuerism showed 65% donor cells. The immunosuppressive kemia (AML) have little hope of prolonged survival. 1 treatment was stopped immediately and cytoreductive therSecond BMT offers a better outcome than conventional apy was administered consisting of cytarabine 10 mg/m 2 chemotherapy but mortality and morbidity remain signifibid for 14 days followed by donor PBSC infusion. The cant. Alternative immunotherapy using donor leukocyte number of mononuclear cells given to the patient was infusions, 2 or a combination of immunotherapy and chemo-55. 
1 treatment was stopped immediately and cytoreductive therSecond BMT offers a better outcome than conventional apy was administered consisting of cytarabine 10 mg/m 2 chemotherapy but mortality and morbidity remain signifibid for 14 days followed by donor PBSC infusion. The cant. Alternative immunotherapy using donor leukocyte number of mononuclear cells given to the patient was infusions, 2 or a combination of immunotherapy and chemo-55. The patient developed chronic persistent GVHD and 13+ al. 17 Our case confirms that persistent chronic GVHD seems to play an essential role in prevention of leukemic months after her last relapse she still remains in cytogenetic and hematological CR, the longest period of CR she has relapse after DLT. The threshold of T lymphocytes required to induce ever had. Steroid treatment is currently being tapered and GVHD seems under control with azathioprine (2 × 50 mg/ GVHD varies from patient to patient and also with the delay between BMT and DLT. Some authors have reported day p.o.) and methylprednisolone (8 mg/day p.o.).
that a progressive increase in the number of T cells can result in an optimal GVL effect associated with mild GVHD.
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Discussion
We conclude that (1) this therapeutic approach combining low-dose chemotherapy and DLT induced a longer AML patients relapsing early after allogeneic BMT have an extremely poor prognosis even when a second bone marrow remission (13+ months) than intensive radiochemotherapy and allogeneic BMT; (2) a GVL effect can be obtained transplantation is given. DLT is currently the most promising approach despite two frequent complications, GVHD even if a patient experienced previous aGVHD after BMT; and (3) the administration of G-CSF primed donor PBSC and marrow aplasia.
We report a patient with very aggressive AML, in relapse allows not only a T cell induced GVL effect but also supplies CD34 + cells that support accelerated hematopoietic 3 months after allogeneic BMT. The patient achieved a 13 month CR after low-dose chemotherapy and donor PBSC recovery after cytoreductive therapy. (CD34 + and T lymphocytes) without any immunosuppressive treatment. This case not only illustrates the major References impact of immunotherapy in the setting of allogeneic BMT but also contributes additional data in terms of DLT- pressive treatment. However although 49 × 10 8 /kg T cells
